Dan Wessler

Biotech / breakout trader. Tweets are just my opinion. Assume I may have any security I am talking about. Best of luck out there.

[Dan Wessler @danwessler]

Updated link (Spravato PIV ECHO trial update): https://t.co/X0f5kjKbWE

[Dan Wessler @danwessler]

$DFTX - Gapped up, fell, then closed green. Analysts are only focused on GAD data but the MDD readout will be first. If this one-time treatment has better efficacy than Spravato with few adverse events, look out. https://t.co/CjBPPatSUA

[Dan Wessler @danwessler]

$DFTX - New 52 week. Breakout continues. Maybe some short covering?

[Dan Wessler @danwessler]

$DFTX - Establishing a base at $20. The HFs that loaded up at $12.25 are already up 68% in 5 months. SI fell from 19% to 15% in the last update.
https://t.co/KcRP93NGDm

[Dan Wessler @danwessler]

$DKS - I love the price weakness off the Foot Locker acquisition. If this hits $180 I will grab some calls.

[Dan Wessler @danwessler]

$DFTX - Definium hits a new 52 wk high & closes over $19. HC Wainwright gave it a $70 PT just 8 days ago & SI is up to 19.5%. DT120 MDD PIII data late 2Q

[Dan Wessler @danwessler]

@Biotech2k1 Hello fellow bio trader! 👋

[Dan Wessler @danwessler]

$MNMD - Mind med breaks out, up 14.6%. Existing anxiety drugs cause liver damage. MM120 had a great PIIb trial. JAMA article & BTD have changed the game for $MNMD

[Dan Wessler @danwessler]

$FNM - First Nordic Metals, gold miner, has a great looking chart for penny stock / microcap investors

[Dan Wessler @danwessler]

$DKS - 3-month chart shows higher levels of support. $250/share was the resistance level but it may eventually become the support level.

[Dan Wessler @danwessler]

@127Lzr I do not have a PT on bluebird but it could keep moving up. The company is cheap and they will inevitably do an offering. Depending on how that goes it could then make a second move.

[Dan Wessler @danwessler]

$BLUE - Reverse split pop. Bluebird trading under cash. Show me another 75 million market cap bio /w 3 FDA approved gene therapies. You won't find one.

[Dan Wessler @danwessler]

@biotech_cash TG is moving back up again towards $35. Pullback to $30 was not much of a buying opportunity for new longs but it was there. Lots of institutional interest

[Dan Wessler @danwessler]

$BLUE - 79 mil volume & up 105% on the day. 3 FDA approvals but they lose $$$ every quarter. New CFO and more patients = someone is betting big on a turnaround story.

[Dan Wessler @danwessler]

@biotech_cash TG made an amazing move today. It has been moving well since the last earnings but today was a surprise.

[Dan Wessler @danwessler]

$TGTX - Triple topped at $23 and broke through this time. Very bullish. Briumvi sales keep increasing and IND to azer-cel CAR T MS therapy goes into P1 soon.

[Dan Wessler @danwessler]

$BLUE - Is this a buy with a new CFO to help with the process of getting the quarterly and annual reports restated correctly? It is trading 55 million under cash and triple touched .65 cents before rebounding.

[Dan Wessler @danwessler]

$CLRB - A lot of "sell the news" folks headed for the exits yesterday but new longs jumped in today. Still sporting a bargain basement market cap after data which is what happens when you dirty your ticker /w 1-10 reverse splits. Stay long.

[dough @semodough]

$CLRB 75.6% Overall Response Rate; 61% Major Response Rate (95% CI, 44.5%, 75.8%); 100% Disease Control Rate exceeding protocol statistical hurdle of 20%
•Median Duration of Response not yet reached with a median of 8 months follow up

[Dan Wessler @danwessler]

$TGTX - Surprisingly strong Briumvi sales of $25 mln is a great number to build off of. They just need to get past the "early adopters" phase IMHO.